Login to Your Account



Ofatumumab BLA Expected by Year-End

Streamlining Genmab Cuts 100 Jobs, Drops Pivotal CTCL Drug

By Jennifer Boggs


Thursday, October 9, 2008
Gearing up for potential commercialization of its lead program, ofatumumab, in chronic lymphocytic leukemia next year - and taking into account the current economic environment - Danish antibody firm Genmab A/S is cutting roughly 15 percent of its work force and halting work on a Phase III program in cutaneous T-cell lymphoma. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription